Article
Clinical Features and HLA Association of 5-Aminosalicylate (5-ASA)-induced Nephrotoxicity in Inflammatory Bowel Disease.
Journal of Crohn's & colitis - 1 Feb 2016
Heap Graham A, So Kenji, Weedon Mike, Edney Naomi, Bewshea Claire, Singh Abhey, Annese Vito, Beckly John, Buurman Dorien, Chaudhary Rakesh, Cole Andrew T, Cooper Sheldon C, Creed Tom, Cummings Fraser, de Boer Nanne K, D'Inca Renata, D'Souza Richard, Daneshmend Tawfique K, Delaney Michael, Dhar Anjan, Direkze Natalie, Dunckley Paul, Gaya Daniel R, Gearry Richard, Gore Steve, Halfvarson Jonas, Hart Ailsa, Hawkey Chris J, Hoentjen Frank, Iqbal Tariq, Irving Peter, Lal Simon, Lawrance Ian, Lees Charlie W, Lockett Melanie, Mann Stephen, Mansfield John, Mowat Craig, Mulgrew Chris J, Muller Frank, Murray Charles, Oram Richard, Orchard Tim, Parkes Miles, Phillips Rosemary, Pollok Richard, Radford-Smith Graham, Sebastian Shaji, Sen Sandip, Shirazi Tarek, Silverberg Mark, Solomon Laurie, Sturniolo Giacomo C, Thomas Mark, Tremelling Mark, Tsianos Epameinondas V, Watts David, Weaver Sean, Weersma Rinse K, Wesley Emma, Holden Arthur, Ahmad Tariq
Abstract excerpt
BACKGROUND AND AIMS: Nephrotoxicity is a rare idiosyncratic reaction to 5-aminosalicylate (5-ASA) therapies. The aims of this study were to describe the clinical features of this complication and identify clinically useful genetic markers so that these drugs can be avoided or so that monitoring can be intensified in high-risk patients. METHODS: Inflammatory bowel disease patients were recruited from 89 sites...
Read the complete abstract on PubMed